X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2177) 2177
Publication (425) 425
Book Chapter (26) 26
Book Review (16) 16
Conference Proceeding (6) 6
Magazine Article (6) 6
Dissertation (5) 5
Book / eBook (1) 1
Government Document (1) 1
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
varenicline (1973) 1973
humans (1349) 1349
index medicus (1215) 1215
smoking cessation (916) 916
male (868) 868
smoking cessation - methods (790) 790
female (759) 759
adult (618) 618
smoking (577) 577
middle aged (564) 564
receptor partial agonist (531) 531
nicotine (511) 511
benzazepines - therapeutic use (501) 501
quinoxalines - therapeutic use (498) 498
nicotinic agonists - therapeutic use (489) 489
smoking-cessation (462) 462
sustained-release bupropion (445) 445
pharmacology & pharmacy (435) 435
psychiatry (430) 430
smoking cessation programs (426) 426
bupropion (382) 382
treatment outcome (378) 378
substance abuse (364) 364
tobacco (333) 333
nicotine replacement therapy (326) 326
smokers (321) 321
article (291) 291
benzazepines - adverse effects (285) 285
quinoxalines - adverse effects (284) 284
placebo (279) 279
cessation (278) 278
efficacy (277) 277
bupropion - therapeutic use (276) 276
animals (270) 270
nicotinic agonists - adverse effects (249) 249
neurosciences (242) 242
medicine, general & internal (229) 229
randomized controlled-trial (226) 226
aged (225) 225
tobacco use disorder - drug therapy (214) 214
smoking - drug therapy (212) 212
young adult (208) 208
nicotinic agonists - administration & dosage (206) 206
varenicline - therapeutic use (195) 195
dependence (194) 194
benzazepines - administration & dosage (192) 192
smoking prevention (192) 192
pharmacotherapy (190) 190
quinoxalines - administration & dosage (189) 189
analysis (187) 187
public, environmental & occupational health (187) 187
nicotinic agonists - pharmacology (186) 186
double-blind method (182) 182
adolescent (181) 181
cigarette-smoking (165) 165
nicotine - administration & dosage (164) 164
smoking cessation - psychology (164) 164
tobacco use cessation products (159) 159
double-blind (156) 156
benzazepines - pharmacology (154) 154
care and treatment (153) 153
quinoxalines - pharmacology (152) 152
smoking - epidemiology (148) 148
rats (145) 145
research (142) 142
dose-response relationship, drug (141) 141
health aspects (141) 141
nicotine dependence (139) 139
smoking - psychology (138) 138
abridged index medicus (133) 133
drug therapy (130) 130
clinical trials (129) 129
abstinence (125) 125
partial agonist (125) 125
smoking - adverse effects (120) 120
therapy (119) 119
addiction (118) 118
risk (116) 116
smoking - therapy (116) 116
pharmacology (115) 115
risk factors (115) 115
safety (115) 115
drug addiction (112) 112
alpha-4-beta-2 (111) 111
counseling (111) 111
nicotine - therapeutic use (107) 107
schizophrenia (106) 106
time factors (104) 104
mortality (102) 102
receptors, nicotinic - metabolism (102) 102
usa (95) 95
smoking cessation products (92) 92
tobacco dependence (91) 91
nicotine - pharmacology (90) 90
drugs (89) 89
follow-up studies (89) 89
placebo-controlled trial (89) 89
intervention (86) 86
united states (86) 86
depression (85) 85
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2026) 2026
German (50) 50
Spanish (49) 49
French (34) 34
Japanese (12) 12
Czech (9) 9
Korean (6) 6
Polish (6) 6
Portuguese (5) 5
Dutch (4) 4
Russian (4) 4
Turkish (4) 4
Chinese (3) 3
Swedish (3) 3
Danish (2) 2
Italian (2) 2
Romanian (2) 2
Finnish (1) 1
Hungarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
11/2010
Varenicline is used to treat tobacco dependence. While varenicline decreases craving during a quit attempt, no studies have investigated its effect on... 
varenicline | 0419 | cue-induced craving
Dissertation
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2016, Volume 2016, Issue 5, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Smoking [drug therapy] | Varenicline | Humans | RANDOMIZED CONTROLLED-TRIAL | Quinolizines [therapeutic use] | PSYCHIATRIC ADVERSE EVENTS | TOBACCO-DEPENDENCE TREATMENT | Quinoxalines [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Bupropion [therapeutic use] | Nicotine [adverse effects; antagonists & inhibitors] | REPLACEMENT THERAPY | SUSTAINED-RELEASE BUPROPION | Smoking Cessation [methods] | Counseling [methods] | VARENICLINE TREATMENT | METHADONE-MAINTAINED SMOKERS | Randomized Controlled Trials as Topic | Azepines [therapeutic use] | DOUBLE-BLIND PLACEBO | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | Azocines [therapeutic use] | LONG-TERM SAFETY | Benzazepines [therapeutic use] | PLACEBO-CONTROLLED TRIAL | Substance Withdrawal Syndrome [prevention & control] | Heterocyclic Compounds with 4 or More Rings [therapeutic use] | Quinolizines - therapeutic use | Azepines - adverse effects | Azocines - therapeutic use | Azocines - adverse effects | Substance Withdrawal Syndrome - prevention & control | Alkaloids - adverse effects | Benzazepines - adverse effects | Smoking - drug therapy | Heterocyclic Compounds, 4 or More Rings - adverse effects | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Quinolizines - adverse effects | Varenicline - therapeutic use | Bupropion - therapeutic use
Journal Article
Journal Article
Journal Article
Tobacco Induced Diseases, ISSN 1617-9625, 10/2019, Volume 17, Issue 1
Objective Smokers with diabetes show higher risk for serious microvascular and macrovascular complications, leading them to greater mortality risk. Moreover... 
varenicline | smoking cessation | diabetics
Journal Article
Biological Psychiatry, ISSN 0006-3223, 2010, Volume 67, Issue 8, pp. 715 - 721
Background Cognitive alterations are a core symptom of nicotine withdrawal, contributing to smoking relapse. In rodents and humans, cognitive deficits can be... 
Psychiatry | varenicline | fMRI | nicotine | withdrawal | Addiction | cognition
Journal Article
Journal Article
Neuropharmacology, ISSN 0028-3908, 03/2007, Volume 52, Issue 3, pp. 985 - 994
The preclinical pharmacology of the α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline, a novel smoking cessation agent is described.... 
Partial agonist | Self-administration | Smoking cessation | Dopamine | nAChR | Varenicline | Nicotine
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 2009, Volume 78, Issue 7, pp. 813 - 824
Effects of the α4β2 nAChR partial agonist varenicline, an efficacious smoking cessation aid, in animal models of addiction, depression, cognition and... 
Depression | Cognition | Addiction | Varenicline | Nicotinic acetylcholine receptors
Journal Article
11/2010
BACKGROUND: Alcohol and tobacco misuse and dependence are highly comorbid disorders. Varenicline alleviates symptoms of cigarette craving while preventing... 
Tobacco | Cue reactivity | Varenicline | 0572 | Alcohol | 0491
Dissertation